PriveBio is a precision medicine biotech focused on developing first-in-class therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases (obesity, heart failure (HFpEF), NASH/MASH, and chronic kidney diseases (DKD)). Leveraging a world-class patient-data platform and ensemble of preclinical mechanism models to inform target identification, validation, patient phenogroups, and biomarkers, we aim to achieve data in patients within 12 months from FIH and POC within 24 months.